This study is examining whether two new treatments, Tarcocimab Tedromer and Tabirafusp Tedromer, are safe and effective for those with neovascular (wet) age-related macular degeneration (wAMD). This eye condition can cause vision loss. The study compares these treatments to a medication called Aflibercept, which is already used for wAMD. People who want to join must have a condition called choroidal neovascularization (CNV) due to age-related macular degeneration. They should not have had any treatment for it before. You must have a certain vision range, measured by a test called BCVA, which checks how many letters you can read on an eye chart. You can’t join if you have very poor vision in the non-study eye or a large area of eye damage.

• Study Duration: The study might last several months, with regular visits.
• Compensation: Participants may receive reimbursement for time and travel.
• Risks: There might be side effects or risks similar to those of other eye treatments.